Highlight
– Pazopanib significantly improved progression-free survival (PFS) compared to placebo in advanced extrapancreatic neuroendocrine tumors (epNETs).
– The majority of patients had midgut primary tumors and prior somatostatin analog (SSA) treatment.
– Despite PFS benefit, pazopanib was associated with higher rates of severe adverse events including grade 5 deaths.
– No significant overall survival benefit was observed, leading to the decision not to pursue further development of pazopanib in this indication.
